Green tea extract to prevent liver cancer in cirrhosis
Part of Cancer, Digestive system clinical trials.
This trial tests whether a green tea extract called EGCG can prevent liver cancer in people with cirrhosis. It looks at how the extract affects liver cell changes that could lead to cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have been diagnosed with cirrhosis (scarring of the liver).
- Your liver is currently stable (no recent serious complications like fluid buildup or bleeding).
- You have never had liver cancer before.
- Your blood tests show your liver, kidneys, and blood cells are working well enough.
- You are able to care for yourself (score of 70 or higher on a daily activity scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug erlotinib can help prevent liver cancer in people with advanced liver scarring or cirrhosis. It might help by stopping liver cells from becoming cancerous.
This trial is testing whether taking a low dose of aspirin every day can lower the risk of developing liver cancer (hepatocellular carcinoma, or HCC) in people with liver cirrhosis. Liver cirrhosis is scarring of the liver, and having it increases the risk of liver cancer. If you are eligible, you would be asked to take aspirin or a placebo (a pill with no active medicine) and have regular check-ups to see if aspirin helps prevent cancer.
This trial tests whether taking a herbal supplement (icariin soft capsules) along with a standard liver cancer treatment called TACE (chemoembolization) can help prevent cancer from returning after you've had it removed. It's for people with high-risk features that make recurrence more likely.
This study looks at whether a short session of endurance exercise (like brisk walking) can change certain proteins in your blood that may help control liver cancer. It is for people with liver cancer and cirrhosis who are already planning to receive immunotherapy or chemoembolization.
This study tests whether offering an ultrasound and a blood test (alpha-fetoprotein) every 6 months can help find liver cancer early in people with cirrhosis (scarred liver) caused by conditions other than hepatitis B or C. The goal is to reduce deaths from liver cancer in this group.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Hear when a new Cirrhosis, Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.